Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

Group 1 - Benitec Biopharma Limited (BNTC) closed at $13.18, with a 9.8% gain over the past four weeks, and a mean price target of $24.71 suggests an 87.5% upside potential [1] - The mean estimate includes seven short-term price targets with a standard deviation of $6.07, indicating variability among analysts; the lowest estimate is $17.00 (29% increase), while the highest is $32.00 (142.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 52.3%, with four estimates moving higher and no negative revisions in the last 30 days [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]